AFAlyssa Fedorko

Alyssa Fedorko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alyssa Fedorko has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Im Kim

    Department of Obstetrics, Gynecology and Reproductive Biology, Michigan State University, Grand Rapids, Michigan, United States of America

    3 shared publications
  • Elizabeth Friedman

    Spectrum Health, Grand Rapids, Michigan, United States of America

    2 shared publications
  • Gadisetti V.R. Chandramouli

    GenEpria Consulting Inc., Columbia MD, USA

    2 shared publications
  • John I. Risinger

    Michigan State University, Grand Rapids, MI

    2 shared publications
  • Rusheeswar Challa

    Michigan State University, Grand Rapids, MI

    2 shared publications
  • Thomas P. Conrads

    Womens Health Integrated Research Center at Inova Health System, Annandale, VA

    2 shared publications

Latest Publications

  • Open Access

    Return to work rates of workers compensation patients with lumbar radiculopathy following epidural steroid injection

    by Sean Pickard, David Speach, Kurt Hauber, Wesley Edwards, Andrea Baran, Alyssa Fedorko

  • Open Access

    An immune competent orthotopic model of endometrial cancer with metastasis

    by Alyssa M. Fedorko, Tae Hoon Kim, Russell Broaddus, Rosemarie Schmandt, Gadisetti V.R. Chandramouli, Hong Im Kim, Jae-Wook Jeong, John I. Risinger


  • Open Access

    Ornithine decarboxylase as a therapeutic target for endometrial cancer

    by Hong Im Kim, Chad R Schultz, Andrea L Buras, Elizabeth Friedman, Alyssa Fedorko, Leigh Seamon, Gadisetti V R Chandramouli, G Larry Maxwell, André S Bachmann, John I Risinger

    Ornithine Decarboxylase (ODC) a key enzyme in polyamine biosynthesis is often overexpressed in cancers and contributes to polyamine-induced cell proliferation. We noted ubiquitous expression of ODC1 in our published endometrial cancer gene array data and confirmed this in the cancer genome atlas (TCGA) with highest expression in non-endometrioid, high grade, and copy number high cancers, which have the worst clinical outcomes. ODC1 expression was associated with worse overall survival and increased recurrence in three endometrial cancer gene expression datasets. Importantly, we confirmed these findings using quantitative real-time polymerase chain reaction (qRT-PCR) in a validation cohort of 60 endometrial cancers and found that endometrial cancers with elevated ODC1 had significantly shorter recurrence-free intervals (KM log-rank p = 0.0312, Wald test p = 5.59e-05). Difluoromethylornithine (DFMO) a specific inhibitor of ODC significantly reduced cell proliferation, cell viability, and colony formation in cell line models derived from undifferentiated, endometrioid, serous, carcinosarcoma (mixed mesodermal tumor; MMT) and clear cell endometrial cancers. DFMO also significantly reduced human endometrial cancer ACI-98 tumor burden in mice compared to controls (p = 0.0023). ODC-regulated polyamines (putrescine [Put] and/or spermidine [Spd]) known activators of cell proliferation were strongly decreased in response to DFMO, in both tumor tissue ([Put] (p = 0.0006), [Spd] (p<0.0001)) and blood plasma ([Put] (p<0.0001), [Spd] (p = 0.0049)) of treated mice. Our study indicates that some endometrial cancers appear particularly sensitive to DFMO and that the polyamine pathway in endometrial cancers in general and specifically those most likely to suffer adverse clinical outcomes could be targeted for effective treatment, chemoprevention or chemoprevention of recurrence.


  • Abstract 1242: Ornithine decarboxylase as a therapeutic target in endometrial cancer

    by Hong Im Kim, Chad R. Schultz, Andrea L. Buras, Elizabeth Friedman, Alyssa M. Fedorko, Leigh G. Seamon, Gadisetti Chandramouli, André S. Bachmann, John I. Risinger

    Endometrial cancer is the 4th most common cancer and the 6th deadliest cancer in US women. The American Cancer Society estimates there will be 60,050 new endometrial cancers in 2016, an increase of more than 10% from the previous year highlighting the need for more effective treatments and prevention. Ornithine Decarboxylase (ODC) a key enzyme in polyamine synthesis is often overexpressed in cancers and contributes to cell proliferation and tumor growth. Therefore, ODC and the polyamine pathway are considered rational targets for cancer treatment or prevention. We noted ubiquitous expression of ODC1 in our previously published endometrial cancer gene array data and confirmed this in the cancer genome atlas (TCGA), finding expression in all four molecular sub-types with highest expression in copy number high cancers which have the worst clinical outcomes. Therefore, we explored the association of ODC1 gene expression with clinical outcomes of overall survival (OS) and recurrence in the TCGA cohort and noted that elevated ODC1 was significantly related to OS (Wald test p=0.001) and recurrence (p=0.01). Importantly, we confirmed these observations using QRT-PCR in a validation cohort of 60 endometrial cancers and found that endometrial cancers with elevated ODC1 had significantly shorter recurrence-free intervals (p=5.59x10-5) and elevated hazard ratio=3.72. Similar to TCGA data we also noted a strong trend to worse OS ( p=0.00014) with elevated hazard ratio 3.81. Numerous studies including clinical trials have examined the chemopreventive and anti-tumor effects of difluoromethylornithine (DFMO), a specific inhibitor of ODC. We found that DFMO treatment significantly reduced cell proliferation, cell viability, and colony formation in human cell line models derived from undifferentiated, endometrioid, serous, MMT and clear cell endometrial cancers. In contrast, immortalized uterine endometrial epithelial cells (EM E6/E7 TERT1) were less sensitive to DFMO. To confirm the significant effects of DFMO in vitro we performed an in vivo study with human endometrial cancer (ACI-98) tumor-bearing athymic nude mice. Xenografted mice were either treated with 2% (w/v) DFMO supplied in drinking water or water only (n=10/group). DFMO significantly reduced the tumor burden in mice compared to controls (p=0.0023). ODC-regulated polyamines (putrescine [Put] and spermidine [Spd]) known activators of cell proliferation were strongly decreased in response to DFMO, in both tumor tissue ([Put] (p=0.0006), [Spd] (pCitation Format: Hong Im Kim, Chad R. Schultz, Andrea L. Buras, Elizabeth Friedman, Alyssa M. Fedorko, Leigh G. Seamon, Gadisetti Chandramouli, André S. Bachmann, John I. Risinger. Ornithine decarboxylase as a therapeutic target in endometrial cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1242. doi:10.1158/1538-7445.AM2017-1242

  • Abstract LB-111: Elevated CXXC5 is associated with recurrence, poor overall survival and cell viability in endometrial cancer

    by Alyssa Fedorko, Gadisetti V.R. Chandramouli, Hong Im Kim, Yutaka Shoji, Rusheeswar Challa, Kathleen M. Darcy, Guisong Wang, Julian Schink, Thomas P. Conrads, John Risinger

    Endometrial cancer is the fourth most common cancer in women and the most prevalent gynecologic malignancy in the United States, however, there has been little improvement in treatment strategies. This problem will become more eminent in the future as the incidence and prevalence of this disease is increasing overall. As it did decades ago, determination of therapeutic modality still relies heavily on two subjective measures: surgical staging and pathological classification. Thus, new markers are needed to more objectively assess disease state and predict potential progression. We have used two independent datasets (Internal and TCGA) containing quantified measures of the transcriptome derived from both serous and endometrioid endometrial cancers to identify upregulated transcripts that are predictive of overall survival (OS) and/or disease-free survival (DFS). In initial analysis of our internal dataset we identified 114 transcripts at p70%) reduction in colony formation and also had increased levels of caspase 3/7 activity. Overall, our results suggest that elevated CXXC5 levels promote cell viability in endometrial cancers overexpressing CXXC5. Thus, CXXC5 could serve not only as a predictive clinical marker for poor outcome disease, but also as a potential novel therapeutic target. Citation Format: Alyssa Fedorko, Gadisetti V.R. Chandramouli, Hong Im Kim, Yutaka Shoji, Rusheeswar Challa, Kathleen M. Darcy, Guisong Wang, Julian Schink, Thomas P. Conrads, John Risinger. Elevated CXXC5 is associated with recurrence, poor overall survival and cell viability in endometrial cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-111.


  • Abstract LB-127: Enrichment of chromosome 1 and 6p21 genes associated with worse progression-free and overall survival in endometrial cancer patients

    by Rusheeswar Challa, Gvr Chandramouli, Alyssa Fedorko, Thomas P. Conrads, John I. Risinger

    Endometrial cancers are generally considered to have favorable outcomes. However, recurrent, and/or non-endometrioid types and some high-grade endometrioid lesions often have very poor survival with limited treatment options. The genes specifically associated with these poor outcomes are not well described. The integrated genomic characterization of endometrial cancers was published in 2013 and the associated RNA-Seq data of these uterine corpus cancers are publicly available at The Cancer Genome Atlas [Nature 497 (7447):67-73]. However, studies on the association of gene expression with the overall survival and recurrence of these endometrial cancers are not yet reported. In this work, we identify those genes associated with survival and recurrence endpoints. RSEM Normalized RNA-Seq (UNC Illumina HiSeq RNASeq V2, level 3) data was downloaded from the TCGA website and survival data extracted from this resource. Cox regression analysis was performed using the survival package in R-environment. The cohort of the patients used in this study cover a large proportion of endometrioid type, while the remaining are serous and mixed histologic types. The proportion of grades 1 to 3 is 84:101:168 and stages I & II (low) to III & IV (high) is 263:87. The ratio of microsatellite unstable to stable cases is about 1:2 approximately both in living and diseased. The tissues were not micro-dissected leaving tumor infiltrates, stroma and other debris. This analysis identified 160 genes significant at p ≤ 0.001 for either overall survival and recurrence free survival or both. In the overall survival analysis, 82 genes were at hazard ratio (HR) ≥ 1 and 48 were at HR ≤ 1. We noted that chromosome 1 was over-represented among gene locations from these gene transcripts. In addition to enrichment of chromosome 1 genes we noted a cluster of genes located on 6p21 with elevated hazard ratios associated with poor clinical outcome. Ontology analysis of the survival associated genes was assessed by EASE software which pointed out the immune response genes have hazard ratios under 1 suggesting that it is a predominant mechanism associated with positive clinical outcome. The finding of immune response genes association with positive clinical outcome (HR ≤ 1) is provocative that prompts further investigation in the assessment and therapy of endometrial cancer. The enrichment of genes on chromosomes 1 and 6 offer further clues to the mechanisms underlying those endometrial cancers with poor clinical outcome. Citation Format: Rusheeswar Challa, GVR Chandramouli, Alyssa Fedorko, Thomas P. Conrads, John I. Risinger. Enrichment of chromosome 1 and 6p21 genes associated with worse progression-free and overall survival in endometrial cancer patients. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-127. doi:10.1158/1538-7445.AM2015-LB-127